vs

Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $20.2M, roughly 1.8× La Rosa Holdings Corp.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -304.2%, a 276.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 3.2%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs 60.5%).

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

LRHC vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.8× larger
RXRX
$35.5M
$20.2M
LRHC
Growing faster (revenue YoY)
RXRX
RXRX
+678.6% gap
RXRX
681.7%
3.2%
LRHC
Higher net margin
LRHC
LRHC
276.9% more per $
LRHC
-27.4%
-304.2%
RXRX
Faster 2-yr revenue CAGR
LRHC
LRHC
Annualised
LRHC
72.5%
60.5%
RXRX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LRHC
LRHC
RXRX
RXRX
Revenue
$20.2M
$35.5M
Net Profit
$-5.5M
$-108.1M
Gross Margin
8.4%
59.8%
Operating Margin
-24.7%
-304.8%
Net Margin
-27.4%
-304.2%
Revenue YoY
3.2%
681.7%
Net Profit YoY
-125.7%
39.6%
EPS (diluted)
$-5.44
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LRHC
LRHC
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$20.2M
$5.2M
Q2 25
$23.2M
$19.2M
Q1 25
$17.5M
$14.7M
Q4 24
$17.7M
$4.5M
Q3 24
$19.6M
$26.1M
Q2 24
$19.1M
$14.4M
Q1 24
$13.1M
$13.8M
Net Profit
LRHC
LRHC
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-5.5M
$-162.3M
Q2 25
$78.4M
$-171.9M
Q1 25
$-95.7M
$-202.5M
Q4 24
$-5.1M
$-178.9M
Q3 24
$-2.5M
$-95.8M
Q2 24
$-2.3M
$-97.5M
Q1 24
$-4.6M
$-91.4M
Gross Margin
LRHC
LRHC
RXRX
RXRX
Q4 25
59.8%
Q3 25
8.4%
-183.8%
Q2 25
8.0%
-4.9%
Q1 25
8.8%
-48.0%
Q4 24
8.9%
-181.4%
Q3 24
8.3%
53.7%
Q2 24
8.3%
36.2%
Q1 24
8.9%
19.1%
Operating Margin
LRHC
LRHC
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-24.7%
-3327.6%
Q2 25
-10.6%
-916.8%
Q1 25
-26.7%
-1297.9%
Q4 24
-17.1%
-4042.4%
Q3 24
-8.9%
-377.1%
Q2 24
-9.7%
-697.4%
Q1 24
-35.0%
-698.4%
Net Margin
LRHC
LRHC
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-27.4%
-3135.3%
Q2 25
337.8%
-894.2%
Q1 25
-546.5%
-1373.3%
Q4 24
-28.7%
-3935.5%
Q3 24
-12.5%
-367.5%
Q2 24
-12.2%
-676.6%
Q1 24
-35.1%
-662.4%
EPS (diluted)
LRHC
LRHC
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-5.44
$-0.36
Q2 25
$15.25
$-0.41
Q1 25
$-5.86
$-0.50
Q4 24
$28.54
$-0.56
Q3 24
$-16.49
$-0.34
Q2 24
$-12.49
$-0.40
Q1 24
$-0.35
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LRHC
LRHC
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$4.0M
$743.3M
Total DebtLower is stronger
$642.8K
$9.6M
Stockholders' EquityBook value
$1.6M
$1.1B
Total Assets
$21.7M
$1.5B
Debt / EquityLower = less leverage
0.41×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LRHC
LRHC
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$4.0M
$659.8M
Q2 25
$5.1M
$525.1M
Q1 25
$2.9M
$500.5M
Q4 24
$1.4M
$594.4M
Q3 24
$1.8M
$427.6M
Q2 24
$1.6M
$474.3M
Q1 24
$1.1M
$296.3M
Total Debt
LRHC
LRHC
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$642.8K
$11.9M
Q2 25
$644.3K
$14.2M
Q1 25
$645.9K
$16.4M
Q4 24
$647.6K
$19.0M
Q3 24
$649.2K
$20.5M
Q2 24
$650.8K
$22.9M
Q1 24
$652.4K
Stockholders' Equity
LRHC
LRHC
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.6M
$1.0B
Q2 25
$3.4M
$919.1M
Q1 25
$-87.5M
$933.9M
Q4 24
$2.6M
$1.0B
Q3 24
$5.0M
$524.6M
Q2 24
$4.7M
$584.4M
Q1 24
$5.6M
$401.2M
Total Assets
LRHC
LRHC
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$21.7M
$1.4B
Q2 25
$22.9M
$1.3B
Q1 25
$21.0M
$1.3B
Q4 24
$19.4M
$1.4B
Q3 24
$19.7M
$726.5M
Q2 24
$18.7M
$775.9M
Q1 24
$16.3M
$557.8M
Debt / Equity
LRHC
LRHC
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.41×
0.01×
Q2 25
0.19×
0.02×
Q1 25
0.02×
Q4 24
0.25×
0.02×
Q3 24
0.13×
0.04×
Q2 24
0.14×
0.04×
Q1 24
0.12×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LRHC
LRHC
RXRX
RXRX
Operating Cash FlowLast quarter
$-1.3M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LRHC
LRHC
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-1.3M
$-117.4M
Q2 25
$-1.4M
$-76.4M
Q1 25
$-3.5M
$-132.0M
Q4 24
$-1.1M
$-115.4M
Q3 24
$-591.6K
$-59.2M
Q2 24
$-803.1K
$-82.2M
Q1 24
$-538.3K
$-102.3M
Free Cash Flow
LRHC
LRHC
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
LRHC
LRHC
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
LRHC
LRHC
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
LRHC
LRHC
RXRX
RXRX
Q4 25
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons